Dicarbine is an orally active drug approved in Russia under the trade name Карбидин, is used for the treatment patients with schizophrenia and alcoholic psychosis. This drug blocks dopamine receptors in various brain parts, which leads to a reduction in the productive symptoms of psychosis: delusions and hallucinations.

Cilobradine is an Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker patented by a pharmaceutical company Boehringer Ingelheim G.m.b.H. for sinus tachycardia treatment. In clinical trials Cilobradine decrease Heart rate. Chronically increased heart rate (HR) is a risk factor for mortality and morbidity with adverse consequences on vascular function, atherogenesis, myocardial ischemia, myocardial energetics and left the ventricular function. Heart rate response was found to be concentration-dependent and appeared with a significant delay with respect to the time course of cilobradine in plasma.

Rilmakalim (HOE-234) is a potassium channel activator and dilator of bronchial and vascular smooth muscles. An animal study showed that rilmakalim is effective against contractile response induced by asthma mediators in guinea pig airways and has the potential to act against asthma attacks, because it acts on acute bronchospasm. The activation of ATP-sensitive potassium channels is likely to be involved in the smooth muscle relaxation produced by rilmakalim in human airways. This drug has been investigated for use in asthma and coronary disorders, but development has been discontinued.

Vinpoline was studied as a central stimulant. Information about the further development of this agent is not available.

Traxoprodil (CP-101,606) is a potent, selective N-Methyl-D-aspartate (NMDA) receptor (NR2B subunit) antagonist under development by Pfizer for its potential as a neuroprotectant in head injury and neurodegenerative disease. It is in phase II trials in the US and in phase I in Japan for the potential treatment of head injury, such as, Depressive Disorder, Major and Parkinson's Disease. CP-101,606 does not protect against glutamate-induced neurotoxicity in cultured cerebellar neurons, up to a dose of 10 uM. These results are consistent with CP-101,606 being a potent NMDA antagonist, selective for the type of NMDA receptor associated with the hippocampus. Some further investigation revealed that CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.

Fenalcomine is a coronary vasodilator, cardiotonic and local anesthetic agent. It was studied in the treatment of angina pectoris.

Amiquinsin hydrochloride, 4-amino-6,7-dimethoxquinoline hydrochloride hydrate, is a drug, which exhibits hypotensive activity. Amiquinsin has a more prolonged hypotensive effect than the hydroxyquinoline.

Bertosamil was developed as an anti-ischemic and anti-arrhythmic drug that inhibits the atrial potassium channels Kv1.2, Kv1.4 and Kv1.5. However, the development of this drug has been discontinued.

Metrifudil (previously known as Y-341) is a synthetic adenosine analog that is acid stable and has a prolonged duration of action. Metrifudil is a selective adenosine A2 receptor agonist and has anticonvulsant activity against seizures. The drug is also studied for the treatment of glomerulonephritis. However, no recent development has been reported.

There is no information about pharmacological and biological properties of epicainide. It is known, that drug was a potent antiarrhythmic agent.